Evaluation of Abuse Potential of Synthetic Cannabinoids and Phytocannabinoids Using In Vivo Pharmacological Studies
Closed Solicitation Posted
- Solicitation number
- 15DDHQ25Q00000010
- Agency
-
Drug Enforcement Administration
Department of Justice
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Drug Enforcement Administration (DEA) is seeking a contractor to conduct comprehensive in vivo pharmacological studies evaluating the abuse potential of synthetic cannabinoids and phytocannabinoids. The solicitation (RFQ 15DDHQ25Q00000010) requires a qualified research institution to perform specialized scientific assessments including locomotor activity assays, drug discrimination studies, and cannabinoid tetrad studies on various test substances. Contractors must possess a Schedule I researcher registration and demonstrate capability to obtain necessary test drugs, conduct rodent-based studies, and provide detailed investigational reports. The DEA will evaluate quotes using a best value trade-off approach, with non-price technical factors being significantly more important than cost considerations. Quotes are due by April 8, 2025, with potential bidders required to submit detailed personnel qualifications, transition plans, management approaches, and past performance examples.
The solicitation is not set aside for any specific business category and is open to organizations within NAICS codes including Colleges, Universities, Medical Laboratories, Research and Development, and Testing Laboratories. The contract covers a base period from May 1, 2025, to April 30, 2026, with four additional one-year option periods extending potentially through May 1, 2029. Each ordering period involves testing 17 total drugs (15 test drugs and 2 reference drugs) across multiple assay types, with specific focus on synthetic opioids in the first period and hallucinogenic substances in subsequent periods. The place of performance is within the United States, and contractors will be responsible for purchasing reference and test substances, performing preclinical studies, and providing comprehensive documentation to the DEA. While specific award values are not explicitly stated, the solicitation includes detailed pricing templates for contractors to complete, indicating a structured approach to cost proposal submission.
Notice text
Investigational study results and a description of the methodology used to conduct the investigation in the form of a study report based on the timeline specified in the statement of work (SOW) for RFQ 15DDHQ25Q00000010
Files
| File | Type | Posted |
|---|---|---|
| 15DDHQ25Q00000010 Amendment 0001 03192025.pdf | ||
| Pricing Sheet Templalte.xlsx | XLSX spreadsheet | |
| RFQ 15DDHQ25Q00000010.pdf | ||
| PRICING SHEET TEMPLATE - Attachment 1.xlsx | XLSX spreadsheet | |
| Sample BPA Call Order - Attachment 2.xlsx | XLSX spreadsheet |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | No set-aside | |
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity